The FDA approved Casgevy, the first CRISPR treatment for sickle cell disease, at $2.2 million per patient.

How it works:

• Edits bone marrow stem cells to produce healthy hemoglobin

• One-time procedure vs lifelong blood transfusions

Controversies:

• "Designer baby" ethical concerns

• Insurance coverage battles

• Global access inequality (90% of sickle cell patients are in Africa)

This milestone opens doors for CRISPR treatments targeting 6,000+ genetic disorders.

The FDA approved Casgevy, the first CRISPR treatment for sickle cell disease, at $2.2 million per patient.

How it works:

• Edits bone marrow stem cells to produce healthy hemoglobin

• One-time procedure vs lifelong blood transfusions

Controversies:

• "Designer baby" ethical concerns

• Insurance coverage battles

• Global access inequality (90% of sickle cell patients are in Africa)

This milestone opens doors for CRISPR treatments targeting 6,000+ genetic disorders.